<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460963</url>
  </required_header>
  <id_info>
    <org_study_id>AML2220</org_study_id>
    <nct_id>NCT04460963</nct_id>
  </id_info>
  <brief_title>Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches</brief_title>
  <official_title>Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be divided into 5 phases:

        1. Collection of bone marrow and peripheral blood (PB) samples from AML patients at
           diagnosis;

        2. Measurement of Midregional Proadrenomedullin (MR-proADM) plasma concentrations with an
           Immunoluminometric Assay of newly diagnosed AML patients not affected by concomitant
           cardiovascular disease or sepsis.

        3. Analysis of exosomes and microvesicles derived from PB and bone marrow samples of AML
           patients and culture media collected from AML samples stimulated with ADM and/or ADM
           (22-52)

        4. Study of adrenomedullin system in leukemic stem cells (CD44+/CD38-/CD31+/Lin-) in order
           to define a correlated expression of ADM and ADM receptors (RAMPs, PAM) with adhesion
           molecules (CD31, CD38, CD44s, CD44v6), cell cycle regulatory proteins (p21, p27) and
           genes or molecules involved in the hematopoietic differentiation process (Cul5, CD11b,
           CD11c, CD66, CD14, CD15, PML-RARÎ±)

        5. In vitro evaluation of ADM activity in the growth, maturation and trans-endothelial
           migration of blasts and/or fusion of leukemic cells with endothelial cells. To do this,
           leukemic cells will be alternatively cultured by using in vitro models of endosteal and
           vascular niches.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of therapeutic potential of ADM inhibition on leukaemia stem cells</measure>
    <time_frame>at 1 year</time_frame>
    <description>Rate estimation of the in vitro arrest of leukemic blasts proliferation by ADM inhibition.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Biological evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adrenomedullin</intervention_name>
    <description>Adrenomedullin sample evaluation</description>
    <arm_group_label>Biological evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with new diagnosis of primary or secondary AML.

          2. Participant is willing and able to give signed written informed consent according to
             ICH/EU/GCP and national local laws.

          3. Male or Female, aged &gt;18 years.

        Exclusion Criteria:

          1. Patients affected by concomitant cardiovascular disease , such as essential
             hypertension (any grade), chronic renal failure (creatinine&gt;1.5 mg/dL), heart failure
             (any NYHA class), and peripheral arterial occlusive diseases, or sepsis.

          2. Patients affected by HIV, B or C hepatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adrenomedullin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

